Clinical trial
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate…
NCT00048659 · Astellas Pharma Inc, Industry · Terminated
Key facts
| NCT number | NCT00048659 |
|---|---|
| Title | YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma US, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hormone-Refractory Prostate Cancer, Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | YM598 |
| Completion | Jun 1, 2004 |
| First posted | Nov 6, 2002 |
| Last update posted | Jun 7, 2012 |
| Countries | Australia, Belgium, France, Germany, Ireland, Netherlands, Poland, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: